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The Phosphatidyl inositol-3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) and c-Met signaling
pathways are often deregulated in cancer. The two pathways are interconnected and at least c-Met has been
implicated in drug resistance. The aim of the study was to assess in ovarian cancer preclinical models, the efficacy
and tolerability of a dual PI3K mTOR inhibitor (PF-05212384 or gedatolisib) and a c-Met inhibitor (crizotinib) either
as single agents or in combination. In vitro, both PF-05212384 and crizotinib showed a concentration dependent
activity in the two ovarian cancer cell lines. The combination of the two did not result in synergistic activity. A
subline resistant to gedatolisib was obtained and showed an increased expression of MDR-1 gene. In vivo results
show that crizotinib alone did not display any activity in all the tumors investigated, while PF-05212384 alone had
some marginal activity. The combination of the two resulted in all the experiments superior to single agents with a
good tolerability. Considering that crizotinib did not show activity in the models used, the results indicate that
crizotinib is able to potentiate the activity of PF-05212384. Although the activity of the combination was not striking
in these three models of ovarian cancer, due to the good tolerability of the combination, the results would suggest
the possibility to combine the two drugs in settings in which gedatolisib or crizotinib alone have already some
significant activity.
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The PI3K/Akt/mTOR pathway is among the most frequently altered
signaling network in human cancers [1–3]. It is involved in several
physiological and pathological processes, including cancer, thus
making it an attractive pathway to target.
The PI3Ks are members of a conserved family of lipid kinases
which are grouped into three classes, I (the most studied in cancer), II
and III, according to their substrate preference and sequence
homology [4,5]. Activation of PI3K leads to the activation of several
proteins, among which Akt plays a central role. Activated Akt is in
turn able to phosphorylate many target proteins and regulate many
cellular functions. The main consequences of Akt activation, relevant
to cancer, are cell survival, proliferation and growth. Among the
downstream effectors, an important role is played by the mTOR.
mTOR is present in two distinct complexes inside the cells, a
rapamycin and nutrient-sensitive multiprotein complex (mTORC1)
and a growth factor sensitive but nutrient insensitive and rapamycin
insensitive complex (mTORC2). Interestingly mTOR, whenassembled in the mTORC2 complex, is able to phosphorylate Akt,
thus suggesting that mTOR can function either upstream or
downstream to Akt [6–9].
Several molecules are being tested for their ability to inhibit the
PI3K/Akt/mTOR pathway. There are available molecules with high
specificity for specific isoforms of PI3K, molecules with pan
inhibitory activity, as well as dual inhibitors able to simultaneously
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inhibitors of PI3K/Akt/mTOR pathway are now under preclinical
and clinical development and some of them have been clinically
approved in selected malignancies, as is the case of the mTOR
inhibitors everolimus and temsirolimus for pancreatic neuroendo-
crine tumors and renal cell carcinoma [10,11], of the delta isoform
specific PI3K inhibitor idelalisib for relapsed chronic lymphocytic
leukemia and indolent lymphomas [12,13].
Despite the strong efficacy of the inhibitors in the pharmacological
modulation of the PI3K/Akt/mTOR pathway at preclinical level,
their therapeutic clinical efficacy has been well below the expectan-
cies. This has been ascribed to several factors: their lack of specificity,
which does not cause an effective inhibition because of off-targets
effects limiting the dosages, the existence of feedback loops, as is for
example the case of Akt activation following mTORC1 inhibition by
rapalogues, and finally the development of resistance [14–16].
Finally the PI3K/Akt/mTOR pathway is interconnected to
different other receptor-mediated signaling which can work together
to sustain the growth of cancer cells. Among these, c-Met receptor has
been shown to activate PI3K/Akt/mTOR pathway [17,18] and to
play an important role in drug resistance [19]. In this context we
assessed in vivo, in ovarian cancer xenografts and patient-derived
xenograft (PDX) with altered PI3K/Akt/mTOR pathway, the activity
of the dual PI3K-mTOR inhibitor PF-05212384 (gedatolisib) and
crizotinib, a widely used c-Met inhibitor, as single agents or in
combination, with the idea that these compounds could synergize,
acting at different levels on the same pathway highly deregulated
in cancer.
Material and Methods
Cell Cultures and Drugs
The human ovarian cancer cell lines A2780 (with deletion in
PTEN gene) and SKOV3 (harboring H1047R mutation in PIK3CA
gene) were grown in vitro in RPMI1640 supplemented with
10% FBS.
Crizotinib and PF-05212384 were obtained from Pfizer and
solutions prepared as recommended.
In Vitro Cytotoxicity Assays
The growth inhibitory activity of crizotinib and PF-05212384 was
determined in vitro by using the MTS test. Cells were seeded in 96Figure 1. In vitro activity of PF-05212384 and crizotinib as single age
increasing concentrations of PF-05212384 (PF) and crizotinib (CZ) f
experiments and SD are shown.wells plates and after 24 hours treated with increasing concentrations
of the drugs for further 72 hours. Survival curves were plotted as
percentages of untreated controls, consisted of at least six replicates for
each time point and represented the average mean and SD of at least
three independent experiments.
Real-Time PCR
RNA was extracted by using Maxwell 16LEV simplyRNA Cells kit
(Promega). RNA was retro-transcribed to cDNA using High Capacity
cDNA Reverse Transcription Kit (Life Technologies). Differences in
MDR-1 gene expression were determined by real-time RT-PCR
performed with Sybr Green PCR master mix (Promega) and the
dissociation curve was evaluated for each gene. Samples were then
normalized using the expression of the housekeeping gene (actin) and
their levels were compared to control samples. Real-time PCR was
done using the 7900HT Sequence Detection System (Applied
Biosystems).
The c-Met gene copy number was assessed using the TaqMan
Copy Number Assay (Applied Biosystems) with the ABI 7900,
Applied Biosystems. hTERT copy number was used as reference gene.
Animals and In Vivo Activity
Female NCr-nu/nu mice (6 weeks old) were obtained from
ENVIGO RMS srl (Correzzana, Italy). They were maintained under
specific pathogen free conditions, housed in isolated vented cages and
handled using aseptic procedures. The IRCCS-Istituto di Ricerche
Farmacologiche Mario Negri adheres to the principles set out in the
following laws, regulations, and policies governing the care and use of
laboratory animals: Italian Governing Law (D. lg 26/2014; Authori-
zation n.19/2008-A issued March 6, 2008 by Ministry of Health);
Mario Negri Institutional Regulations and Policies providing internal
authorization for persons conducting animal experiments (Quality
Management System Certificate- UNI EN ISO 9001:2008 – Reg,
No.6121); the NIHGuide for the Care and Use of Laboratory Animals
(2011 edition) and EU directives and guidelines (EEC Council
Directive 2010/63/UE). The Statement of Compliance (Assurance)
with the Public Health Service (PHS) Policy on Human Care and Use
of Laboratory Animals was recently reviewed (9/9/2014) and will expire
on September 30, 2019 (Animal Welfare Assurance #A5023–01).
Human A2780 and SKOV-3 cells (5x106 cells/mouse) were
injected subcutaneously (sc) in immunodeficient mice. The human
ovarian PDX MNHOC218 [20,21], containing three copies of thents. Response of A2780 (A) and SKOV3 (B) cell lines treated with
or 72 h, detected by MTS assay. The average of 3 independent
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Figure 2. In vitro activity of the combination of PF-05212384 and crizotinib. Response of A2780 and SKOV3 cells treated with PF-05212384
as single agent or in combination with crizotinib, detected by MTS assay. Cells were treated for 72 h with non cytotoxic concentrations of
the two drugs using different schedules: PF-05212384 was administered for 24 h and followed by crizotinib for 48 h (A and D), crizotinib
was followed after 24 h by PF-05212384 (B and E) or the two drugs were given simultaneously (C and F). The average of 3 independent
experiments and SD are shown.
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through trocar needles.
When the tumor reached approximately 100–150 mm3, they were
treated with PF-05212384 10 mg/kg intravenous (iv) Q4dx4,
crizotinib 50 mg/kg per os (po) every day or with the combination
of the two drugs.
Tumor growth was measured with a Vernier caliper every 2
to 3 days and tumor weights (mg = mm3) were calculated using
the formula: (length [mm]*width [mm]2)/2. The efficacy
of the treatment was expressed as best tumor growth inhibition
[%T/C = (mean tumor weight of treated tumors/mean tumor weight
of control tumors)*100]. For all the experiments, a T/C b42% is
considered the minimum level for activity [22].
Western Blotting Analysis
Total proteins were purified from snap frozen tumors after
homogenation in 50 mM Tris HCl pH 7.4, 250 mM NaCl, 0.1%
Nonidet NP-40, 0.5 mM EDTA and NaF 50 mM, in the presence of
aprotinin, leupeptine and phenyl-methyl-sulfonyl-fluoride (PMSF) as
proteases inhibitors (ratio 1: 1 w/v). Lysates were cleared by
centrifuging at 13,000×g for 20 min and protein concentration was
determined using a Biorad assay kit (BioRad, Italy). Around 30 μg of
total protein extracts were loaded on 12% SDS-PAGE and then
transferred to a PVDF membrane. Primary antibodies anti
phopho-Akt (Ser473), p-Akt (Thr308), Akt, p-4EBP1 (Thr37/46),
4EBP1, p-S6 (Ser235/236) and S6 were purchased from Cell Signaling
Technology; anti p-ERK (Tyr204) and ERK were purchased from
Santa Cruz Biotechnology. Antibody binding was revealed by
peroxidase labeled secondary antibodies and visualized using
enhanced chemioluminescence (Amersham, Italy).Statistical Analyses
The statistical analyses were performed using Graphpad Prism
version 6. Specific tests used to analyze specific experiments are
indicated in the legends coupled to the figures. Differences between
groups were considered statistically significant when the P ≤ .05.
Results
In Vitro Activity of Crizotinib and PF-05212384
The in vitro inhibitory activity of crizotinib and PF-05212384 in
A2780 and SKOV3 cells is reported in Figure 1 panels A and B,
respectively. For both drugs, a concentration dependent activity was
found, with SKOV3 cells slightly more sensitive to PF-05212384
treatment and A2780 cells slightly more sensitive to crizotinib.
The combination of PF-05212384 and crizotinib was tested
in vitro using drugs concentrations non-cytotoxic as single treatments.
This did not result in a greater response in both A2780 and SKOV3
cell lines (Figure 2). The effect observed was, in fact, ascribable to
PF-05212384 treatment, as similar results were obtained in response
to either the single-drug or to the combined treatments. This finding
was strengthened by the use of a different treatment schedule. Indeed,
to verify whether the effect observed was dependent on the
experiment schedule, cells were treated for 24 hours with one of
the two drugs and for the remaining 48 hours with the other one.
After 24 hours of treatment with PF-05212384 (Figure 2, panels A
and D), cells did not respond significantly to either the drug singly or
to the combination. When crizotinib was followed after 24 hours by
PF-05212384 treatment (Figure 2, panels B and E), a similar
concentration-dependent growth inhibition was observed in
PF-05212384-treated cells and in cells treated with the combination,
PF-05212384 [µM] CRIZOTINIB [µM]
Figure 3. Characterization of SKOV3 cell line resistant to PF-05212384. A. c-Met gene copy number in SKOV3 parental cell line and SKOV3
cell line resistant to PF-05212384 (SKPF), assessed using the TaqMan Copy Number Assay and using hTERT copy number as reference
gene. B. Relative expression levels of MDR-1 in SKPF at two different culture passages. mRNA expression at basal conditions was
assessed by Real-Time PCR and relative expression levels were calculated with ΔΔCt method, setting SKOV3 parental cell line as
reference sample (=1). A-B. The histograms represent the average mean and SD of 3 technical replicates. C-D. In vitro activity of
PF-05212384 (C) and crizotinib (D) in SKOV3 parental cell line and in SKPF. The average of 3 independent experiments and SD are shown.
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in agreement with those obtained after the simultaneous treatment
with the two drugs for 72 hours, which, however, was slightly more
effective (Figure 2, panels C and F).
Characterization of SKOV3 Cell Line Resistant to
PF-05212384
In order to get more insights into the response mechanisms to the
combination, attempts were made to have a cell line resistant to
PF-05212384 with amplification of c-Met gene. However, SKOV3
cells treated with PF-05212384 developed resistance with normal
c-Met gene copies (Figure 3A), but with a very high expression of
MDR-1 gene (Figure 3B). Figure 3 reports the activity of
PF-05212384 in parental SKOV3 cells and in the resistant subline
(SKPF). As it can be seen, the resistant cell line did not respond to the
drug anymore (Figure 3, panel C and Table 1). In parallel we haveTable 1. Statistical Analysis of PF-05212384 Response in SKOV3 and SKPF, Reported in
Figure 3C
PF-05212384 [μM]
0.0005 0.001 0.005 0.01 0.05 0.1 0.5 1 5
SKOV3 vs. SKPF ns ns ns ** **** **** **** **** ****
The analysis was performed using two-way ANOVA test and Bonferroni post-test for multiple
comparisons. ** P b .01, **** P b .0001.evaluated the activity of crizotinib in SKOV3 and SKPF cells and the
drug showed the same activity in both cell lines (Figure 3, panel D).
We next analyzed the cytotoxic response of SKPF to the
combination of the two drugs (Figure 4). As already seen for the
parental cell line, no differences were detected in response to either
the single-drug or to the combined treatment. In fact, nor the single
treatment with PF-05212384 or the combination were active on the
resistant cell line, even when a different schedule was used. The
combination was not able to restore SKPF sensitivity, confirming that
the addition of crizotinib to PF-05212384 does not enhance the
effect of the treatment.
In Vivo Activity of Crizotinib and PF-05212384
When tested in vivo, A2780-bearing mice showed a very limited
activity of both crizotinib and PF-05212384 (Figure 5A). The
combination of the two showed some activity. The T/Cx100 values
were close to 100 for both drugs as single agent and reached roughly
70 for the combination (Figure 5B). The increased activity was not
associated with increased toxicity, as judged by the body weight of the
animals that was, for all the groups tested, similar to that of
vehicle-treated mice (Figure 5C).
A similar picture was observed in SKOV3 xenografts (Figure 6A).
In this case, in agreement with what observed in vitro, this tumor
better responded to PF-05212384 with a T/Cx100 value of 82, while
the growth of tumors treated with crizotinib was even faster than that
of untreated mice. Interestingly the combination resulted active with
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Figure 4. Dose–response curves of SKPF treated with the combination of PF-05212384 and crizotinib. Response of SKPF treated with
increasing concentrations of PF-05212384 as single agent or in combination with a non toxic concentration of crizotinib, detected byMTS
assay. Cells were treated for 24 h with one of the two drugs and for 48 h with the other one or the two drugs were given simultaneously for
72 h. The average of 3 independent experiments and SD are shown.
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uneffective in this model, the combination seemed to have a higher
antitumor activity. Again also in this model the combination was well
tolerated with no differences in body weight decrease between
combination and single agents (Figure 6C).
We then moved to a PDX model selecting a tumor with negative
staining for PTEN and presenting an additional copy of both c-Met
and PIK3CA genes. In this model (Figure 7A and Table 2) crizotinib
showed some initial activity, but then the tumors started growing at
the same rate of untreated mice. PF-05212384 had some activity
with a T/Cx100 of 67 but the combination was much more active
reaching a T/Cx100 of 38 (Figure 7B). In this case an initial drop in
body weight was observed for the group treated with the
combination, which however completely recovered in few days
(Figure 7C).Figure 5. Antitumor activity of PF-05212384, crizotinib or the combi
A2780 xenografts, treated with PF-05212384 10 mg/kg iv Q4dx4 (gre
combination of the two drugs for 13 days. B. Percentage of tumor g
Body weight of A2780 bearing mice treated with PF-05212384, criz
analysis was performed using two-way ANOVA test and Bonferroni poPharmacodynamic Studies
The effect of single agents or of the combination on PI3K and
MAPK pathways activation in vivo was determined by Western blot
analysis performed on lysates from tumors explanted 24 hours after
treatment in A2780 and SKOV3-derived xenografts (Figure 8, A
and B, respectively). In A2780 xenograft model crizotinib alone had a
partial inhibitory effect and induced a slight increase in the amount of
p-Akt (Thr308), whose pattern was almost unaffected in samples
treated with PF-05212384 or the combination. PF-05212384 mainly
inhibited p-S6 (Ser235/236) and p-Akt (Ser473) and this effect was not
boosted by the addition of crizotinib in the combination. A lower
extent of p-Akt (Ser473) was also detected in SKOV3-derived
xenografts (Figure 8B) upon both single-drug and combined
treatments. In this model, Akt (Thr308) and S6 phosphorylation
state was marginally affected by PF-05212384 or the combination,nation in A2780 xenografts. A. Tumor growth inhibition activity of
en arrows), crizotinib 50 mg/kg po every day (red line) or with the
rowth inhibition (T/C%) calculated for all the treatment groups. C.
otinib or the combination. Means and SEM are shown. Statistical
st-test for multiple comparisons and no differences were detected.
Figure 6. Antitumor activity of PF-05212384, crizotinib or the combination in SKOV3 xenografts. A. Tumor growth inhibition activity of
SKOV3 xenografts, treated with PF-05212384 10 mg/kg iv Q4dx4 (green arrows), crizotinib 50 mg/kg po every day (red line) or with the
combination of the two drugs for 13 days. B. Percentage of tumor growth inhibition (T/C%) calculated for all the treatment groups. C.
Body weight of SKOV3 bearing mice treated with PF-05212384, crizotinib or the combination. Means and SEM are shown. Statistical
analysis was performed using two-way ANOVA test and Bonferroni post-test for multiple comparisons and no differences were detected.
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Analysis of p-4EBP1 (Thr37/46) and p-ERK (Tyr204) did not reveal
clear changes in any of the models used.Figure 7. Antitumor activity of PF-05212384, crizotinib or the combina
MNHOC218 PDX, treated with PF-05212384 10 mg/kg iv Q4dx4 (gre
combination of the two drugs for 13 days. B. Percentage of tumor g
Body weight of MNHOC218 PDX bearing mice treated with PF-0521Discussion
The PI3K/Akt/mTOR pathway is one of the most deregulated
signaling pathway in cancer. Several inhibitors of the pathway havetion in the PDX MNHOC218. A. Tumor growth inhibition activity of
en arrows), crizotinib 50 mg/kg po every day (red line) or with the
rowth inhibition (T/C%) calculated for all the treatment groups. C.
2384, crizotinib or the combination. Means and SEM are shown.
Table 2. Statistical Analysis of the In Vivo Antitumor Activity Reported in Figure 7A
Day
15 18 23 25 28 30 32 35 37 39 42
CTRL vs. PF ns ns ns ns ns ns ns ns ns ns ns
CTRL vs. CZ ns ns ns ns ns ns ns ns ns ns ns
CTRL vs. CZ + PF ns ns ns ns ns * ns * ** **** ****
PF vs. CZ ns ns ns ns ns ns ns ns ns ns ****
PF vs. CZ + PF ns ns ns ns ns ns ns ns ns ns *
CZ vs. CZ + PF ns ns ns ns ns ns ns * ** **** ****
The analysis was performed on the mean tumor weight calculated for all the treatment groups,
using two-way ANOVA test and Bonferroni post-test for multiple comparisons. *P b .1, ** P b .01,
**** P b .0001.
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clear predictive marker for the response to PI3K/Akt/mTOR
inhibitor is still lacking, it is generally accepted that tumors
with activated PI3K pathway respond to treatment with PI3K
inhibitors. It is however expected that these tumors, after an
initial response, will develop resistance as it has been reported
for other PI3K inhibitors.
Among the possible resistance mechanisms, amplification/overex-
pression of c-Met represents a common mechanism of resistance to
chemotherapy, particularly following tyrosine kinase inhibitors (TKI)
[23–25]. There is preclinical evidence that tumors dependent on
PI3K can develop resistance through c-Met amplification [26,27].
Additional experimental evidence indicates a cross-talk between
c-Met-dependent and PI3K-dependent signaling which implies that
the combination of PI3K and c-Met inhibitors could have clear
benefits [27].
In our study, we aimed at combining, in ovarian cancer xenografts
and PDX, a dual PI3K mTOR inhibitor (PF-05212384 orFigure 8. Effects of treatment on PI3K and MAPK pathways molecula
treatment with PF-05212384, crizotinib or the combination on A2780 x
Western blot represent protein band intensities of p-Akt (Ser473), p-Ak
relative total protein. Two independent experiments were performedgedatolisib) with crizotinib as c-Met inhibitor. The idea was that the
presence of a continuous treatment with crizotinib would have reduced
the chances to develop resistance to treatment with the PI3K-mTOR
inhibitor. We tested initially the combination in vitro to verify that in
the two cell lines used (A2780 and SKOV3) there was no synergism, to
be sure that the in vivo experiments would have evidentiated a
potentiation of the activity through inhibition of the emerging PI3K
mTOR-resistant clone. Indeed in our system crizotinib per se was
devoid, at the doses used here, of any significant antitumor activity. On
the contrary, in all the three models used it was able to increase the
activity of PF-05212384. Based on our in vitro lack of additivity/
synergism between the two drugs, the increased activity observed could
be possibly associated to the ability of crizotinib to block the
development of c-Met mediated resistant clone.
In our in vitro system we could not derive a PF-05212384 resistant
clone with amplified or overexpressed c-Met, being the clones selected
for resistance in vitro associated to an increased expression of the
efflux pumpMDR-1. This precluded the possibility to test in vivo the
activity of the combination in cells with c-Met associated PI3K
inhibitors resistant clones. However, we can exclude that the superior
antitumor activity of the combination observed in vivo is due to the
ability of crizotinib to prevent MDR-1 positive clones, since in vitro
the combination tested in cells resistant to PF-05212384 and
overexpressing MDR-1 did not result in any significant positive effect
compared to PF-05212384 alone.
The availability of a PDX model with three copies of the c-Met
gene allowed us to test the combination in a model with a modest
increase of c-Met and again we found a superior activity of the
combination.
Pharmacodynamic studies, performed in xenografts, showed
that crizotinib did not change the ability of PF-05212384 to
inhibit the PI3K/Akt/mTOR pathway, again in line with our
initial hypothesis.r effectors. Representative Western blot analysis after 24 hours of
enografts (A) and SKOV3 xenografts (B). The histograms below the
t (Thr308), p-S6 (Ser235/236) levels normalized with the amount of the
.
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In summary, the results obtained in the three models show that
crizotinib alone did not show any activity in all the tumors
investigated, while PF-05212384 alone had some marginal activity.
The combination of the two showed higher activity compared to
drugs alone. Considering that crizotinib did not show activity in the
models used, the results indicate that crizotinib is able to potentiate
the activity of PF-05212384.
The activity of the combination, although superior to the drugs alone,
is not striking in these three models of ovarian cancer. However, due to
the well tolerability of the combination, the results would suggest the
possibility to combine the two drugs in settings in which PF-05212384
or crizotinib alone have already some significant activity.
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